Abstract:A successful treatment of AIDS world-wide is severely hindered by the HIV virus' drug resistance capability resulting from complicated mutation patterns of viral proteins. Such a system of mutations enables the virus to survive and reproduce despite the presence of various antiretroviral drugs by disrupting their binding capability. Although these interacting mutation patterns are extremely difficult to efficiently uncover and interpret, they contribute valuable information to personalized therapeutic regimen design. The use of Bayesian statistical modeling provides an unprecedented opportunity in the field of anti-HIV therapy to understand detailed interaction structures of drug resistant mutations. Multiple Bayesian models equipped with Markov Chain Monte Carlo (MCMC) methods have been recently proposed in this field (Zhang et al. in PNAS 107: 1321, 2010 [1]; Zhang et al. in J Proteome Sci Comput Biol 1: 2, 2012 [2]; Svicher et al. in Antiviral Res 93(1): 86-93, 2012 [3]; Svicher et al. in Antiviral Therapy 16(7): 1035-1045, 2011 [4]; Svicher et al. in Antiviral Ther 16(4): A14-A14, 2011 [5]; Svicher et al. in Antiviral Ther 16(4): A85-A85, 2011 [6]; Alteri et al. in Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 HIV-1 are specifically associated with dual tropism and modulate the interaction with CCR5 N-Terminus, 2011 [7]). Probabilistically modeling mutations in the HIV-1 protease or reverse transcriptase (RT) isolated from drug-treated patients provides a powerful statistical procedure that first detects mutation combinations associated with single or multiple-drug resistance, and then infers detailed dependence structures among the interacting mutations in viral proteins (Zhang et al. in PNAS 107: 1321, 2010 [1]; Zhang et al. in J Proteome Sci Comput Biol 1: 2, 2012 [2]). Combined with molecular dynamics simulations and free energy calculations, Bayesian analysis predictions help to uncover genetic and structural mechanisms in the HIV treatment resistance. Results obtained with such stochastic methods pave the way not only for optimization of the use for existing HIV drugs, but also for the development of the new more efficient antiretroviral medicines. In this chapter we survey current challenges in the bioinformatics of anti-HIV therapy, and outline how recently emerged Bayesian methods can help with the clinical management of HIV-1 infection. We will provide a rigorous review of the Bayesian variable partition model and the recursive model selection procedure based on probability theory and mathematical data analysis techniques while highlighting real applications in HIV and HBV studies including HIV drug resistance (Zhang et al. in PNAS 107: 1321, 2010 [1]), cross-resistance (Zhang et al. in J Proteome Sci Comput Biol 1: 2, 2012 [2]), HIV coreceptor usage (Svicher et al. in Antiviral Therapy 16(7): 1035-1045, 2011 [4]; Svicher et al. in Antiviral Ther 16(4): A14-A14, 2011 [5]; Alteri et al. in Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 HIV-1 are specifically associated with dual tropism and modulate the interaction with CCR5 N-Terminus, 2011 [7]), and occult HBV infection (Svicher et al. in Antiviral Res 93(1): 86-93, 2012 [3]; Svicher et al. in Antiviral Ther 16(4): A85-A85, 2011 [6]).

Classifying Genetic Interactions Using an HIV Experimental Study

Exploring virus relationships based on virus-host protein-protein interaction network

Modeling homophily in dynamic networks with application to HIV molecular surveillance

Systems mapping of HIV-1 infection

Machine Learning Approaches for Predicting Virus-Human Protein-Protein Interactions: An Evaluation of Retroviral Interaction Networks

Integrated Analysis of Human Influenza A (H1N1) Virus Infectionrelated Genes to Construct a Suitable Diagnostic Model

Novel machine learning approach toward classification model of HIV-1 integrase inhibitors

Targeting Virus-host Protein Interactions: Feature Extraction and Machine Learning Approaches

Human Gene Functional Network-Informed Prediction of HIV-1 Host Dependency Factors

Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap Insertional Mutagenesis

Virus-host interactions predictor (VHIP): Machine learning approach to resolve microbial virus-host interaction networks

Incorporating metadata in HIV transmission network reconstruction: A machine learning feasibility assessment

Bayesian analysis of complex interacting mutations in HIV drug resistance and cross-resistance.

DeepViral: prediction of novel virus–host interactions from protein sequences and infectious disease phenotypes

Patterns of HIV-1 Protein Interaction Identify Perturbed Host-Cellular Subsystems

Computational Analysis of HIV-1 Resistance Based on Gene Expression Profiles and the Virus-Host Interaction Network

A comprehensive stochastic computational model of HIV infection from DNA integration to viral burst

Investigating alignment-free machine learning methods for HIV-1 subtype classification

Exploring Viral–Host Protein Interactions as Antiviral Therapies: A Computational Perspective

A functional map of HIV-host interactions in primary human T cells

The Application of High Throughput Sirna Screening Technology to Study Host-Pathogen Interactions.